Ann Med Med Res | Volume 4, Issue 1 | Case Study | Open Access

Use of Rifabutin for Drug-Sensitive Tuberculosis Therapy in HIV/TB Co-Infection: A Case Report

Herbertson EC*, Ekama SO and Onwujekwe DI

Department of Medicine, Nigerian Institute of Medical Research, Nigeria

*Correspondance to: Herbertson EC 

Fulltext PDF


This is a case report person living with HIV, who became co-infected with Tuberculosis (TB) and was treated with rifabutin-based anti-TB regimen while on protease-inhibitor-based ART (September 2015 to March 2016). The treatment site was a busy out-patient HIV clinic in Lagos, Nigeria. There was no report of adverse drug reaction and no treatment interruption in this reported case, this is consistent with the report of less than 5% treatment interruption and no serious ADR among patients. Both antiretroviral and anti-TB therapy outcomes were good with rifabutin in a case of HIV/TB co-treatment for a patient on protease inhibitor-based antiretroviral therapy.


Rifabutin; Tuberculosis; Antiretroviral; Anti-TB therapy; Co-Infection


Herbertson EC, Ekama SO, Onwujekwe DI. Use of Rifabutin for Drug-Sensitive Tuberculosis Therapy in HIV/TB Co- Infection: A Case Report. Ann Med Medical Res. 2021;4:1034.

Subscribe to Our Newsletter